Table 1 Patient characteristics
Population | ||
|---|---|---|
Variable | (n = 65) | |
Age, median (range) | 55 (19–74) | |
Gender, n (%) | Male | 38 (58) |
Female | 27 (42) | |
BMI, kg/m2, median (range) | 22 (16.8–31.8) | |
Time since transplantation, months (range) | 56 (3–162) | |
Donor, n (%) | Living | 63 (97) |
Deceased | 2 (3) | |
Previous SARS-CoV-2 vaccine, doses, median (range) | 4 (0–6) | |
≧ 3 doses, n (%) | 59 (91) | |
≦ 2 doses, n (%) | 5 (7) | |
0 dose, n (%) | 1 (2) | |
Time from symptom onset to initial antiviral treatment, days, median (range) | 1 (0–14) | |
Baseline eGFR, ml/min/1.73m2, median (range) | 45.1 (18.3–99.5) | |
Primary kidney disease, n (%) | Glomerulonephritis | 27 (42) |
DM nephropathy | 11 (17) | |
Polycystic kidney disease | 6 (9) | |
Nephrosclerosis | 4 (6) | |
Others | 8 (12) | |
Unknown | 9 (14) | |
Maintenance immunosuppression, n (%) | Tacrolimus | 60 (92) |
Cyclosporine | 7 (11) | |
Mycophenolate mofetil | 42 (65) | |
Everolimus | 33 (52) | |
Azathioprine | 1 (2) | |
Prednisolone | 60 (92) | |
Methylprednisolone | 3 (5) | |
Comorbidities, n (%) | DM | 19 (29) |
HT | 54 (83) | |
Overweight/obesity | 10 (15) | |
CVD | 13 (20) |